MINNEAPOLIS, MN , Jan. 31, 2018 -- VigiLanz, a digital healthcare intelligence firm, announced today that it has earned 2018 Category Leader designations for Infection Control and Clinical Decision Support-Surveillance in the 2018 Best in KLAS: Software and Services report. These mark the second and third KLAS honors in the past year for VigiLanz, which also achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report for its platform, customer partnerships, and dedication to customer service and support.
In the “2018 Best in KLAS: Software and Services,” report, released on January 30, VigiLanz’s Dynamic Infection Control Monitor™ product garnered a score of 90.3 while its Dynamic PharmacoVigilance® product earned an 89.9.
The Category Leader designation is reserved for vendor solutions that lead select market segments in which at least two products meet a minimum level of KLAS Konfidence. Rankings are based on customer surveys of North American hospital and clinic executives, administrators, physicians, nurses, clinicians, and other directors and managers interacting with healthcare equipment solutions.
Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s standard EHR system. Via an automatic exception-based alert system, all patient records are under continuous surveillance to alert decision makers in real time to potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern and reportable infections. The surveillance is based on a sophisticated set of rule engines that can be customized for each hospital.
Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, the system automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.
“VigiLanz is honored to see our solutions recognized as Category Leaders, particularly as healthcare professionals are the engine that drives KLAS’ impartial research on the software and services used by providers worldwide,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Following upon VigiLanz’ recognition by KLAS in 2017 for our Antimicrobial Stewardship products, these additional designations further validate our reputation among clinicians and administrators alike as a company that offers the best, top-performing solutions in the industry.”
About KLAS
KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.
About VigiLanz
Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.
Media Contact: Erik Johnson, Vice President of Marketing VigiLanz Corp. [email protected] 952.232.6391


Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



